Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

ARCAGY/ GINECO GROUP327 enrolled

Overview

This study aims to understand whether it is possible to predict the effectiveness of maintenance treatment with PARP inhibitors following first-line chemotherapy in ovarian cancer, and thus better target the patients who benefit from this treatment

Study Type

OBSERVATIONAL

Enrollment

327

Conditions

Ovarian Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients randomised in the PAOLA-1 study - Exclusion Criteria:Opposition to the use of your data for research purposes. \-

Locations (24)

ICO Paul Papin

Angers, France

Outcomes

Primary Outcomes

predictive and prognostic value of the KELIM score

To evaluate the predictive and prognostic value of the KELIM score in patients receiving maintenance treatment with a PARP inhibitor as part of the PAOLA-1 clinical trial.

Time frame: 18 months

Central Contacts

Sandra MABALUKIDI

CONTACT

0033 01 84 85 20 23 smabalukidi@arcagy.org

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.